A5047607730- Food Allergy and Anaphylaxis Research
- Allergic Rhinitis and Sensitization
- Eosinophilic Esophagitis
- Asthma and respiratory diseases
- Contact Dermatitis and Allergies
- Respiratory and Cough-Related Research
- Polyomavirus and related diseases
- Pediatric health and respiratory diseases
- Food Safety and Hygiene
- Occupational exposure and asthma
- Drug-Induced Adverse Reactions
- Transgenic Plants and Applications
- Child Nutrition and Feeding Issues
- Viral gastroenteritis research and epidemiology
- Celiac Disease Research and Management
- Infant Health and Development
- Pharmaceutical studies and practices
- Respiratory viral infections research
- Child and Adolescent Health
- Dermatology and Skin Diseases
- Urticaria and Related Conditions
- Breastfeeding Practices and Influences
- Immunodeficiency and Autoimmune Disorders
- Neonatal Respiratory Health Research
- Healthcare Policy and Management
The University of Texas Southwestern Medical Center
2016-2025
Southwestern Medical Center
2013-2024
Children's Medical Center
2016-2018
Trinity House
2016
National Institute of Allergy and Infectious Diseases
2014
Duke Medical Center
2009-2012
Duke University Hospital
2009
Baylor College of Medicine
2008-2009
Alfa Laval (Sweden)
1993
There are currently no approved treatments for peanut allergy.To assess the efficacy and adverse events of epicutaneous immunotherapy with a patch among peanut-allergic children.Phase 3, randomized, double-blind, placebo-controlled trial conducted at 31 sites in 5 countries between January 8, 2016, August 18, 2017. Participants included children (aged 4-11 years [n = 356] without history severe anaphylactic reaction) developing objective symptoms during food challenge an eliciting dose 300...
<h3>Importance</h3> Epicutaneous immunotherapy may have potential for treating peanut allergy but has been assessed only in preclinical and early human trials. <h3>Objective</h3> To determine the optimal dose, adverse events (AEs), efficacy of a patch treatment. <h3>Design, Setting, Participants</h3> Phase 2b double-blind, placebo-controlled, dose-ranging trial peanut-allergic patients (6-55 years) from 22 centers, with 2-year, open-label extension (July 31, 2012-July 2014; completed...
Peanut oral immunotherapy, using a variety of approaches, has been previously shown to induce desensitization in peanut-allergic subjects, but no products have approved for clinical use by regulatory agencies.We performed the first phase 2 multicentered study assess safety and efficacy AR101, novel biologic drug product.A randomized, double-blind, placebo-controlled trial was conducted at 8 US centers. Eligible subjects were 4 26 years old, sensitized peanut, had dose-limiting symptoms ≤143...
The PEPITES (Peanut EPIT Efficacy and Safety) trial, a 12-month randomized controlled study of children with peanut allergy 4 to 11 years old, previously reported the safety efficacy epicutaneous immunotherapy (EPIT) for (250 μg, daily protein; DBV712 250 μg).We sought assess interim an additional 2 from ongoing (5-year treatment) PEOPLE (PEPITES Open-Label Extension) study.Subjects who completed were offered enrollment in PEOPLE. Following subjects had received μg underwent month-36...
The randomized, controlled PALISADE trial demonstrated the benefit of daily oral immunotherapy with Peanut (Arachis Hypogaea) allergen powder-dnfp (PTAH, formerly AR101) in peanut-allergic children and adolescents.ARC004, open-label follow-on study to PALISADE, used 5 dosing cohorts explore PTAH treatment beyond 1 year alternative regimens individuals.Active arm (PTAH-continuing) participants who tolerated 300-mg peanut protein at exit double-blind placebo-controlled food challenge placebo...
BackgroundPrior studies of peanut sublingual immunotherapy (SLIT) have suggested a potential advantage with younger age at treatment initiation.ObjectiveWe studied the safety and efficacy SLIT for allergy in 1- to 4-year-old children.MethodsPeanut-allergic children were randomized receive 4 mg versus placebo. Desensitization was assessed by double-blind, placebo-controlled food challenge (DBPCFC) after 36 months treatment. Participants desensitized least 443 protein discontinued therapy 3...
No approved treatment exists for allergen-specific immunoglobulin E (IgE)-mediated cow's milk allergy (CMA), a common childhood food allergy.
Treatment options for peanut allergy are limited. In previous clinical trials, epicutaneous immunotherapy with a patch containing 250-μg protein (Viaskin Peanut 250 μg [VP250]) was well tolerated and statistically superior to placebo in desensitizing peanut-allergic children.To examine the safety of VP250 children, using study design approximating potential real-world use.REAL LIfe Use Safety EPIT (REALISE) is phase 3 multicenter consisting 6-month, randomized, double-blind,...
This common statement of the American Academy Allergy, Asthma and Immunology (AAAAI) The European Allergy Clinical (EAACI) provides an update 2012 published guidelines on food challenges. equally address challenges in research clinical settings. They first diagnostic tests which can guide decision to conduct a challenge. Safety is prime, various procedures safety issues as well medications potentially involved are extensively discussed. Challenges suggested be conducted with semi-logarithmic...